Nordic Nanovector Appoints Skilled Pharmaceutical Enterprise Chief Erik Skullerud as Chief Government Officer

Oslo, Norway, September 14, 2021 / PRNewswire / – Nordic Nanovector ASA (OSE: NANOV) announces the appointment of. known Erik Skullerud as Chief Executive Officer (CEO). He will take the position on September 20, 2021 and will be based at the company’s headquarters in Zug, Switzerland, divides his time between Zug and the headquarters of Nordic Nanovector in Oslo.

Mr. Skullerud comes from Element Consulting GmbH, a global consulting and consulting boutique specializing in the life science industry, of which he was a co-founder and managing partner.

Prior to founding Element Consulting, Mr. Skullerud spent 25 years in the biopharmaceutical industry with increasing responsibility in global sales and marketing management roles. This included more than 15 years at Amgen, where he was most recently Marketing Director Europe Oncology / Hematology. Before that, he worked for Bayer Pharma for seven years, most recently as Product Group Manager Cardiovascular / Diabetes Scandinavia.

Mr. Skullerud has launched numerous highly innovative products in therapeutic areas such as oncology, hematology, cardiology and nephrology and has significant business management experience in the markets of the EU, Asia and the USA. As a consultant, he has worked with some of the world’s leading pharmaceutical and biotech companies as well as small, highly specialized start-ups on projects ranging from corporate strategy to early and mid-stage rollout and commercialization to late-stage lifecycle projects are sufficient.

Mr. Skullerud is a Norwegian citizen and resides in Switzerland. He holds a BSc in Marketing, Finance and Management from Gothenburg Business School, University of Gothenburg and was visiting professor of the INSEAD MBA program, Paris, France.

Jan H. Egberts, Chairman of the Board of Directors of Nordic Nanovector, said, “I am delighted that Erik has agreed to join Nordic Nanovector in a bigger and more valuable business based on maximizing the commercial potential of Betalutin®. I would like to thank Malene Brondberg for rising to the role of Interim CEO over the past few months, a time when the company has made good progress in implementing its key goals. Malene will continue her role as CFO. “

Mr. Skullerud added: “I am very much looking forward to this new role at Nordic Nanovector. I believe that my experience from around the world in strategy, commercialization, and sales and marketing can help the company move to the next important phase of its development as we work to bring Betalutin® to patients for the first time, an important one Step to realize the greater value of the company. ”

Upon joining Nordic Nanovector, Mr. Skullerud will receive 350,000 PSUs (Performance Share Units).

Further information on the PSUs and the associated warrants can be found on page 28 of the company’s 2020 annual report.

For more information please contact:

IR inquiries

Jan H. Egberts, chairman of Nordic Nanovector
Tel: +31 614672518
Email: [email protected]

Media inquiries

Mark Schwalbe/ Frazer Hall /David Dible (MEDiSTRAVA advice)
Tel: +44 203 926 8535
Email: [email protected]

About Nordic Nanovektor:

Nordic Nanovector is committed to developing and delivering innovative therapies to patients to meet huge unmet medical needs and advance cancer treatment. The company aims to become a leader in the development of targeted therapies for hematological cancers. Nordic Nanovector’s lead candidate in clinical stage is Betalutin®, a novel CD37-targeting antibody-radionuclide conjugate developed to advance the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with significant unmet medical need, which is a growing market forecast of almost. is equivalent to $ 26 billion until 2028. Nordic Nanovector retains the worldwide marketing rights to Betalutin® and intends to participate actively in the commercialization of Betalutin® in the US and other major markets.

More information is available at

Forward-Looking Statements

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainties and changes in circumstances as they relate to events and depend on circumstances that will occur in the future and that will by their nature affect Nordic Nanovector’s business and financial condition and earnings. The terms “anticipate”, “assume”, “believe”, “may”, “could”, “estimate”, “expect”, “forecast”, “intend”, “may”, “could”, “plan”, “Should”, “projects”, “goals”, “will”, “would” or any negative or other variation or equivalent terminology thereof are used to identify forward-looking statements. These forward-looking statements are not historical facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks related to the implementation of Nordic Nanovector’s strategy, risks and uncertainties related to the development and / or approval of Nordic Nanovector’s product candidates, ongoing and future clinical studies and expected Study results, the ability to commercialize Betalutin®, technological changes and new products in the potential market and industry of Nordic Nanovector, Nordic Nanovector’s freedom of action (patents from competitors) with regard to the products it develops, the ability to introduce new products Develop and improve existing products, the effects of competition, changes in general economic and industry conditions, and legal, regulatory and political factors. There can be no assurance that these expectations will prove to be correct. Nordic Nanovector disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events or for any other reason.

This information is subject to a disclosure requirement in accordance with Sections 4-2 and 5-12 WpHG.

This information was made available to you by Cision,c3415106

SOURCE Nordic nanovector